Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection
| Autor: | Clair E. Cox, Christine Grad, Robert E. McCabe |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Male Klebsiella medicine.medical_specialty Cefotaxime Lactams medicine.drug_class Urinary system Cephalosporin Opportunistic Infections medicine.disease_cause Gastroenterology Random Allocation Vancomycin Internal medicine medicine Humans Adverse effect Norfloxacin Aged Aged 80 and over Clinical Trials as Topic Cross Infection biology Pseudomonas aeruginosa business.industry General Medicine Middle Aged biology.organism_classification Anti-Bacterial Agents Surgery Aminoglycosides Superinfection Urinary Tract Infections Female business medicine.drug |
| Zdroj: | The American Journal of Medicine. 82:59-64 |
| ISSN: | 0002-9343 |
| DOI: | 10.1016/0002-9343(87)90620-6 |
| Popis: | In a multiclinic, randomized trial, oral norfloxacin, a fluoroquinolone antibacterial, was compared with several standard parenteral regimens for the treatment of nonbacteremic, hospital-acquired urinary tract infections. Parenteral antibiotic agents included aminoglycosides alone; aminoglycosides in combination with either broad-spectrum penicillins or first-generation cephalosporins; or cefotaxime alone. Ninety-two percent of bacterial isolates were multiresistant gram-negative rods including Pseudomonas aeruginosa (31 percent), Escherichia coil (17 percent), Klebsiella/Enterobacter species (14 percent), and Serratia species (11 percent). In the first evaluable 94 patients, norfloxacin was comparable to the parenteral agents in eliminating infecting bacteria from the urine. Similarly, combined bacterial eradication and clinical cure or improvement occurred in 96 percent (76 percent with cures, 20 percent with improvement) of those treated with norfloxacin and 88 percent (67 percent with cures, 21 percent with improvement) of those treated with parenteral agents. A negative outcome (i.e., failure, superinfection, or reinfection) occurred in two (4 percent) norfloxacin-treated patients versus six (12 percent) parenterally treated patients. Adverse effects were few, infrequently drug related, and rarely serious (one with norfloxacin versus two with parenteral agents). Additionally, drug, preparation, and administration costs were substantially less with oral norfloxacin compared with the parenteral agents. The data suggest, therefore, that oral norfloxacin can be substituted for commonly used parenteral antibiotic regimens, without any compromise in efficacy, in the treatment of nonbacteremic patients with multiresistant, nosocomial urinary tract infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|